Fresenius Medical Care (NYSE:FMS) shares fell 8.0% to €41.285 during Tuesday’s trading session as investors looked beyond better-than-expected second-quarter results and focused instead on continued weakness in U.S. patient treatment volumes.
Although the dialysis provider exceeded analyst forecasts for both revenue and profit, the disappointing treatment trends prompted a sharp sell-off, with the shares opening at €41.16 before falling as low as €40.555 during the session.
Revenue and Profit Surpass Expectations
Fresenius Medical Care reported second-quarter operating income, excluding special items, of €569 million, representing a 23% increase on a currency-adjusted basis and comfortably ahead of the market consensus of €515 million.
Revenue also exceeded expectations, rising to €4.861 billion compared with analyst forecasts of approximately €4.792 billion.
Despite the stronger financial performance, investors remained concerned about the company’s underlying operational trends.
U.S. Treatment Volumes Weigh on Sentiment
The main issue highlighted by the market was a 0.9% year-over-year decline in comparable same-market treatment volumes in the United States.
Analysts viewed the decline as the most important takeaway from the earnings report, raising questions about the sustainability of future growth in Fresenius Medical Care’s largest market.
Analysts Remain Cautious
JPMorgan analyst David Adlington maintained an “Underweight” rating on the stock with a €37.40 price target, arguing that management’s decision to reaffirm, rather than raise, its full-year guidance could lead analysts to lower second-half earnings forecasts.
Jefferies analyst James Vane-Tempest also kept an “Underperform” recommendation and a €31 price target, identifying weaker U.S. treatment volumes as the company’s primary challenge.
“Sell the News” Reaction Hits Shares
The broader market offered little support, with major U.S. indices posting only modest gains during the session.
Fresenius Medical Care ranked among the weakest-performing stocks in the DAX as investors reacted to the combination of solid financial results and an unchanged full-year outlook.
The company’s shares have traded between €34.57 and €47.86 over the past 12 months, reflecting the volatility surrounding expectations for its recovery.
While improved profitability benefited from cost-saving initiatives and favourable U.S. reimbursement rates, the lack of upgraded guidance and continued decline in patient treatment volumes created a classic “sell the news” response, sending the stock well below its previous closing price of €44.86 and reversing part of its recent recovery.
Fresenius Medical Care stock price
